Over a 6-month period, HT use was associated with lower rates of AD biomarker change as reflected in a smaller reduction in Aβ42/p-tau231 ratios, which was more among APOE4 carriers (Depypere et al., 2022), suggesting possible gene–environment effects. Here, APOE is linked to Alzheimer disease.